Smoking Cessation: Medicare Decision May Give OTC Products A New Angle
This article was originally published in The Pink Sheet Daily
Executive Summary
National coverage determination could lead to 2.8 mil. new eligible beneficiaries for treatment. OTCs and prescription nicotine replacement therapy products could get a boost as a result of the decision, assuming other private plans follow suit.
You may also be interested in...
Medicare Coverage Policy Change Opens Up Commercial Market Pathway – If Biden Likes It
Modification to ‘reasonable and necessary’ definition in MCIT final rule offers new avenue for drug manufacturers to get products covered in Part B. The Biden Administration will have to decide whether it will keep the Trump regulation unchanged.
Flaws Of ‘Virtual’ Advisory Committees Highlighted At Aducanumab Panel
The intensely negative advisory committee for Biogen’s proposed Alzheimer’s therapy was a shocker. Would it have happened if US FDA had been able to convene an in-person event instead of a ‘virtual’ one?
The Greatest FDA Advisory Committees, Part III: The Power of The Patients
With landmark advisory committee meetings coming up, we take a look back at some of the memorable panel meetings over the last 20 years.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: